Literature DB >> 30382180

Bevacizumab or fibronectin gene editing inhibits the osteoclastogenic effects of fibroblasts derived from human radicular cysts.

Hai-Cheng Wang1, Peng Wang2, Yuan-Wei Chen3, Yan Zhang4.   

Abstract

Fibronectin (FN) is a main component of extracellular matrix (ECM) in most adult tissues. Under pathological conditions, particularly inflammation, wound healing and tumors, an alternatively spliced exon extra domain A (EDA) is included in the FN protein (EDA+FN), which facilitates cellular proliferation, motility, and aggressiveness in different lesions. In this study we investigated the effects of EDA+FN on bone destruction in human radicular cysts and explored the possibility of editing FN gene or blocking the related paracrine signaling pathway to inhibit the osteoclastogenesis. The specimens of radicular cysts were obtained from 20 patients. We showed that the vessel density was positively associated with both the lesion size (R = 0.49, P = 0.001) and EDA+FN staining (R = 0.26, P = 0.022) in the specimens. We isolated fibroblasts from surgical specimens, and used the CRISPR/Cas system to knockout the EDA exon, or used IST-9 antibody and bevacizumab to block EDA+FN and VEGF, respectively. Compared to control fibroblasts, the fibroblasts from radicular cysts exhibited significantly more Trap+MNCs, the relative expression level of VEGF was positively associated with both the ratio of EDA+FN/total FN (R = 0.271, P = 0.019) and with the number of Trap+MNCs (R = 0.331, P = 0.008). The knockout of the EDA exon significantly decreased VEGF expression in the fibroblasts derived from radicular cysts, leading to significantly decreased osteoclastogenesis; similar results were observed using bevacizumab to block VEGF, but block of EDA+FN with IST-9 antibody had no effect. Furthermore, the inhibitory effects of gene editing on Trap+MNC development were restored by exogenous VEGF. These results suggest that EDA+FN facilitates osteoclastogenesis in the fibrous capsule of radicular cysts, through a mechanism mediated by VEGF via an autocrine effect on the fibroblasts. Bevacizumab inhibits osteoclastogenesis in radicular cysts as effectively as the exclusion of the EDA exon by gene editing.

Entities:  

Keywords:  EDA+FN; IST-9 antibody; VEGF; bevacizumab; gene editing; odontogenic cysts; osteoclastogenesis; radicular cysts

Mesh:

Substances:

Year:  2018        PMID: 30382180      PMCID: PMC6786368          DOI: 10.1038/s41401-018-0172-x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  29 in total

1.  EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling.

Authors:  Martin Kohan; Andres F Muro; Eric S White; Neville Berkman
Journal:  FASEB J       Date:  2010-07-19       Impact factor: 5.191

Review 2.  The post-endodontic periapical lesion: histologic and etiopathogenic aspects.

Authors:  Celia Carrillo García; Francisco Vera Sempere; Miguel Peñarrocha Diago; Eva Martí Bowen
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2007-12-01

3.  Fibroblasts isolated from a keratocystic odontogenic tumor promote osteoclastogenesis in vitro via interaction with epithelial cells.

Authors:  H-C Wang; W-P Jiang; Z-H Sima; T-J Li
Journal:  Oral Dis       Date:  2014-03-24       Impact factor: 3.511

Review 4.  Regulation of Hematopoiesis and Osteogenesis by Blood Vessel-Derived Signals.

Authors:  Saravana K Ramasamy; Anjali P Kusumbe; Tomer Itkin; Shiri Gur-Cohen; Tsvee Lapidot; Ralf H Adams
Journal:  Annu Rev Cell Dev Biol       Date:  2016-08-17       Impact factor: 13.827

5.  The CRISPR/Cas system inhibited the pro-oncogenic effects of alternatively spliced fibronectin extra domain A via editing the genome in salivary adenoid cystic carcinoma cells.

Authors:  H-C Wang; Y Yang; S-Y Xu; J Peng; J-H Jiang; C-Y Li
Journal:  Oral Dis       Date:  2015-04-06       Impact factor: 3.511

6.  A prospective epidemiological study for odontogenic and non-odontogenic lesions of the maxilla and mandible in Queensland.

Authors:  Nigel R Johnson; Neil W Savage; Stauros Kazoullis; Martin D Batstone
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-04

7.  Tenascin and fibronectin expression in odontogenic cysts.

Authors:  Marcílio Dias Chaves de Oliveira; João Luiz de Miranda; Rivadávio Fernandes Batista de Amorim; Lélia Batista de Souza; Roseana de Almeida Freitas
Journal:  J Oral Pathol Med       Date:  2004-07       Impact factor: 4.253

8.  Identification of the peptide sequences within the EIIIA (EDA) segment of fibronectin that mediate integrin alpha9beta1-dependent cellular activities.

Authors:  Arti V Shinde; Christopher Bystroff; Chunyu Wang; Mariette G Vogelezang; Peter A Vincent; Richard O Hynes; Livingston Van De Water
Journal:  J Biol Chem       Date:  2007-10-29       Impact factor: 5.157

9.  Gene editing of the extra domain A positive fibronectin in various tumors, amplified the effects of CRISPR/Cas system on the inhibition of tumor progression.

Authors:  Wan-Qi Lv; Hai-Cheng Wang; Jing Peng; Yi-Xiang Wang; Jiu-Hui Jiang; Cui-Ying Li
Journal:  Oncotarget       Date:  2017-09-21

10.  Stromal cell-derived factor-1 and its receptor CXCR4 are upregulated expression in degenerated intervertebral discs.

Authors:  Hua Zhang; Li Zhang; Linwei Chen; Wanli Li; Fangcai Li; Qixin Chen
Journal:  Int J Med Sci       Date:  2014-01-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.